NUZYRA opportunities NUZYRA (omadacycline) data presentations at multiple conferences (IDWeek CHEST ATS ESCMID Global) indicate ongoing clinical and real-world evidence generation, suggesting sales opportunities in infectious diseases markets, including hospital and ID physician targets, for expanding use and payer uptake.

Capital support Recent $50 million financing and ongoing investor interest imply financial backing to accelerate commercialization efforts, potential for expanded market access initiatives, and scalable manufacturing or distribution partnerships to grow NUZYRA adoption.

Strategic ownership Acquisition by a larger sponsor (B-FLEXION) positions Paratek as a platform for a diversified specialty portfolio, presenting cross-sell opportunities with other therapies and potential collaborations for repurposing or expanding NUZYRA within related infectious disease indications.

Global conference momentum Frequent participation and data releases at ESCMID Global, IDWeek, ATS, and CHEST signal active engagement with international and US clinician communities, offering relationship-building pathways with key KOLs and hospital procurement teams for formulary discussions.

Public health focus Mission to address life-threatening infectious diseases and partnerships with physicians and caregivers highlight alignment with public health needs, creating opportunities to target government or payer programs, hospital networks, and regional disease burden strategies for NUZYRA adoption and reimbursement.